Immune cell therapy for difficult autoimmune kidney disease
Part of Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests a new immune cell therapy (called STAR-T cells) for two types of autoimmune kidney disease—IgA nephropathy and membranous nephropathy—that haven't responded to usual treatments. The goal is to stop the immune system from attacking the kidneys, which may help reduce protein in urine and preserve kidney function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have been diagnosed with either IgA nephropathy or primary membranous nephropathy, confirmed by a kidney biopsy.
- Your standard treatments haven't worked well enough (still have high protein in urine), or you can't tolerate them, or your kidney function dropped quickly.
- Your kidneys are working at least 30% of normal (eGFR 30 or higher).
- Your blood counts and liver function are within safe limits.
- You are not pregnant and agree to use birth control during the study and for 2 years after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cell therapy called GT719 that targets B cells, part of the immune system that attacks the kidneys in several types of autoimmune kidney disease. It is designed for people whose kidney disease has not improved with standard treatments.
This study tests an experimental cell therapy (CAR-γδ T cells) for people with certain autoimmune kidney diseases that have not responded to usual treatments. The goal is to see if this therapy is safe and can help control the disease.
This early-stage trial tests a new type of cell therapy (CAR-T cells) designed to treat severe autoimmune diseases where the immune system attacks the body's own organs. The therapy targets specific immune cells (B cells) that may be causing the disease. It may help patients who haven't improved with standard treatments or can't tolerate them.
This trial tests a new immune cell treatment (CAR-T) for people with certain kidney diseases—IgA nephropathy or membranous nephropathy—that have not improved with standard care. The therapy aims to calm the immune system to protect the kidneys.
This trial tests a new type of cell therapy called CAR-T cells that target two proteins (BCMA and CD19) to treat autoimmune kidney diseases that are not responding to standard treatments. The goal is to see if this therapy can help control the disease and improve kidney function.
This trial is testing a new kind of immune therapy, called UCAR-T, which uses reprogrammed white blood cells to help treat a severe type of kidney disease (membranous nephropathy) that has not improved with standard medicines. The goal is to see if this therapy can calm the immune attack on the kidneys and reduce protein loss in urine.
Hear when a new IgA Nephropathy (IgAN) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.